OBI is a clinical stage global oncology company that is headquartered in Taiwan and established in 2002. Its mission, together with its wholly owned subsidiary OBI Pharma USA, Inc., is to develop ...

Amicus licenses exclusive U.S. rights to commercialize DMX-200 for the treatmentof Focal Segmental Glomerulosclerosis (FSGS) ...

PD-L1 ISAC directly activates and reprograms PD-L1-expressing myeloid cells in the TME to drive complete responses and immunological memory ...

SOUTH SAN FRANCISCO, CA, USA I April 30, 2025 I Vaxart, Inc. (Nasdaq: VXRT) today announced that it completed enrollment of its Phase 1 clinical trial evaluating its second-generation oral norovirus ...

Preclinical data demonstrates unique binding location of CT-95 on mesothelin and avoidance of binding to shed mesothelin ...

PLAINSBORO, NJ, USA I April 30, 2025 I Today, The New England Journal of Medicine (NEJM) published results from part 1 of the ongoing phase 3 ESSENCE ...

SHANGHAI, China I April 30, 2025 I Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, presented 6 study results ...

CAMBRIDGE, MA, USA I April 30, 2025 I Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced that the first participant has ...

VANCOUVER, Canada I April 29, 2025 I AbCellera (Nasdaq: ABCL) today announced new data on its PSMA x CD3 T-cell engagers (TCEs), presented as a poster at the ...

MARSEILLE, France I April 29, 2025 I Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today shared new preclinical data for ...

AI-designed oligos with goal of making therapies safer and more effective for patients with rare and common diseases ...

BASEL, Switzerland I April 29, 2025 I Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in generic and biosimilar medicines, announced today that it has signed ...